Personalized Medicine for TP53 Mutated Myelodysplastic Syndromes and Acute Myeloid Leukemia

Personalized Medicine for TP53 Mutated Myelodysplastic Syndromes and Acute Myeloid Leukemia

Targeting TP53 mutated myelodysplastic syndromes and acute myeloid leukemia remains a significant unmet need. Recently, new drugs have attempted to improve the outcomes of this poor molecular subgroup. The aim of this article is to review all the current knowledge using active agents including hypom...

Full description

Bibliographic Details
Main Authors:	Thomas Cluzeau, Michael Loschi, Pierre Fenaux, Rami Komrokji, David A. Sallman
Format:	Article
Language:	English
Published:	MDPI AG 2021-09-01
Series:	International Journal of Molecular Sciences
Subjects:	MDS AML TP53 magrolimab eprenetapopt
Online Access:	https://www.mdpi.com/1422-0067/22/18/10105

Similar Items

How I Treat <i>TP53</i>-Mutated Acute Myeloid Leukemia and Myelodysplastic Syndromes
by: Michael Loschi, et al.
Published: (2022-09-01)

Targeting CD47/SIRPα in Acute Myeloid Leukemia and Myelodysplastic Syndrome: Preclinical and Clinical Developments of Magrolimab
by: Fadi Haddad, et al.
Published: (2021-05-01)

TP53 mutation in newly diagnosed acute myeloid leukemia and myelodysplastic syndrome
by: Pimjai Niparuck, et al.
Published: (2021-10-01)

TP-0903 Is Active in Preclinical Models of Acute Myeloid Leukemia with <i>TP53</i> Mutation/Deletion
by: Eric D. Eisenmann, et al.
Published: (2022-12-01)

Are We Moving the Needle for Patients with <i>TP53</i>-Mutated Acute Myeloid Leukemia?
by: Rory M. Shallis, et al.
Published: (2022-05-01)

Immune checkpoint gene VSIR predicts patient prognosis in acute myeloid leukemia and myelodysplastic syndromes
by: Kevin Yao, et al.
Published: (2023-03-01)

Targeting MDM4 as a Novel Therapeutic Approach in Prostate Cancer Independent of p53 Status
by: Javier Octavio Mejía-Hernández, et al.
Published: (2022-08-01)

The Current Understanding of and Treatment Paradigm for Newly-Diagnosed <i>TP53</i>-Mutated Acute Myeloid Leukemia
by: Rory M. Shallis, et al.
Published: (2021-12-01)

Deep Molecular and In Silico Protein Analysis of p53 Alteration in Myelodysplastic Neoplasia and Acute Myeloid Leukemia
by: Kristóf Madarász, et al.
Published: (2022-11-01)

Unmet Horizons: Assessing the Challenges in the Treatment of <i>TP53</i>-Mutated Acute Myeloid Leukemia
by: Christos Stafylidis, et al.
Published: (2024-02-01)

TP53 Alterations in Myelodysplastic Syndromes and Acute Myeloid Leukemia
by: Ramy Rahmé, et al.
Published: (2023-04-01)

Understanding the Continuum between High-Risk Myelodysplastic Syndrome and Acute Myeloid Leukemia
by: Phaedon D. Zavras, et al.
Published: (2023-03-01)

Bladder Myeloid Sarcoma with TP53 mutated Myelodysplastic Syndrome/Myeloproliferative Neoplasm Overlap syndrome: Response to Decitabine-Venetoclax regimen
by: Nikeeta Mandhan, et al.
Published: (2022-01-01)

Molecular characterization of AML‐MRC reveals TP53 mutation as an adverse prognostic factor irrespective of MRC‐defining criteria, TP53 allelic state, or TP53 variant allele frequency
by: Davidson Zhao, et al.
Published: (2023-03-01)

Acute myeloid leukemia cells and MSC-derived exosomes inhibiting transformation in myelodysplastic syndrome
by: Xiaoli Liu, et al.
Published: (2023-06-01)

Mutation spectrum, expression profiling, and prognosis evaluation of Fanconi anemia signaling pathway genes for 4259 patients with myelodysplastic syndromes or acute myeloid leukemia
by: Lixian Chang, et al.
Published: (2023-11-01)

The Differential Expression of CD47 may be Related to the Pathogenesis From Myelodysplastic Syndromes to Acute Myeloid Leukemia
by: Xiao Yan, et al.
Published: (2022-03-01)

A thiol‐bound drug reservoir enhances APR‐246‐induced mutant p53 tumor cell death
by: Sophia Ceder, et al.
Published: (2021-02-01)

Clinical and Cytogenetic Characterization of Early and Late Relapses in Patients Allografted for Myeloid Neoplasms with a Myelodysplastic Component
by: Victoria Platte, et al.
Published: (2022-12-01)

Vemurafenib induces senescence in acute myeloid leukemia and myelodysplastic syndrome by activating the HIPPO signaling pathway: implications for potential targeted therapy
by: Qiao Zhou, et al.
Published: (2024-01-01)

The Role of Inhibition of Apoptosis in Acute Leukemias and Myelodysplastic Syndrome
by: Amanda McBride, et al.
Published: (2019-03-01)

Prediction of Response and Survival Following Treatment with Azacitidine for Relapse of Acute Myeloid Leukemia and Myelodysplastic Syndromes after Allogeneic Hematopoietic Stem Cell Transplantation
by: Christina Rautenberg, et al.
Published: (2020-08-01)

Azacitidine front-line in 339 patients with myelodysplastic syndromes and acute myeloid leukaemia: comparison of French-American-British and World Health Organization classifications
by: Lisa Pleyer, et al.
Published: (2016-04-01)

Clinical, hematological, and cytogenetic profile of adult myelodysplastic syndrome in a tertiary care center
by: Narayanan S
Published: (2017-02-01)

HAPLOIDENTICAL TRANSPLANT WITH POST-TRANSPLANT CYCLOPHOSPHAMIDE FOR ACUTE MYELOID LEUKAEMIA AND MYELODYSPLASTIC SYNDROMES PATIENTS: THE ROLE OF PREVIOUS LINES OF THERAPY.
by: Daniele Avenoso, et al.
Published: (2024-01-01)

Rare case of myelodysplastic syndrome with near-tetraploidy and TP53 mutation
by: Čolović Nataša, et al.
Published: (2023-01-01)

Recent Advances towards the Understanding of Secondary Acute Myeloid Leukemia Progression
by: Scott Auerbach, et al.
Published: (2024-02-01)

TP53 in Myelodysplastic Syndromes
by: Yan Jiang, et al.
Published: (2021-10-01)

<i>TP53</i> Mutation in Acute Myeloid Leukemia: An Old Foe Revisited
by: Dong-Yeop Shin
Published: (2023-09-01)

p53 biology and reactivation for improved therapy in MDS and AML
by: Joanna E. Zawacka
Published: (2024-03-01)

A Clinical Phase 1B Study of the CD3xCD123 Bispecific Antibody APVO436 in Patients with Relapsed/Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome
by: Fatih M. Uckun, et al.
Published: (2021-08-01)

TP53 Mutations in AML Patients Are Associated with Dismal Clinical Outcome Irrespective of Frontline Induction Regimen and Allogeneic Hematopoietic Cell Transplantation
by: Davidson Zhao, et al.
Published: (2023-06-01)

Clinical outcomes and characteristics of patients with TP53-mutated myelodysplastic syndromes
by: Lijuan Zhang, et al.
Published: (2023-12-01)

Acute leukemia / myelodysplastic syndrome as a sequelae of carcinoma breast: A report of five cases from north India
by: Bhatia Prateek, et al.
Published: (2009-04-01)

Targeting the mevalonate or Wnt pathways to overcome CAR T-cell resistance in TP53-mutant AML cells
by: Jan Mueller, et al.
Published: (2024-02-01)

Mutations in Splicing Factor Genes in Myeloid Malignancies: Significance and Impact on Clinical Features
by: Valeria Visconte, et al.
Published: (2019-11-01)

Pevonedistat in East Asian patients with acute myeloid leukemia or myelodysplastic syndromes: a phase 1/1b study to evaluate safety, pharmacokinetics and activity as a single agent and in combination with azacitidine
by: Hiroshi Handa, et al.
Published: (2022-05-01)

Prognostic heterogeneity and clonal dynamics within distinct subgroups of myelodysplastic syndrome and acute myeloid leukemia with TP53 disruptions
by: Shyam A. Patel, et al.
Published: (2023-11-01)

TP53 Mutations in Acute Myeloid Leukemia: Still a Daunting Challenge?
by: Matteo Molica, et al.
Published: (2021-02-01)

The TP53 fertility network
by: Diego d'Avila Paskulin, et al.
Published: (2012-01-01)